These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30642824)

  • 21. Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer.
    van Holstein Y; Kapiteijn E; Bastiaannet E; van den Bos F; Portielje J; de Glas NA
    Drugs Aging; 2019 Oct; 36(10):927-938. PubMed ID: 31317421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.
    Kennedy LC; Bhatia S; Thompson JA; Grivas P
    J Natl Compr Canc Netw; 2019 Jun; 17(6):750-757. PubMed ID: 31200356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
    Asmar N; Ibrahim T; Rey JF
    Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
    [No Abstract]   [Full Text] [Related]  

  • 24. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Rivera Vargas T; Apetoh L
    Front Immunol; 2019; 10():1181. PubMed ID: 31191545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
    Zahavi DJ; Weiner LM
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
    Bermudez MV; Papa S
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii1-vii6. PubMed ID: 31816083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cancer immunotherapy].
    Kjeldsen JW; Donia M; Svane IM
    Ugeskr Laeger; 2018 May; 180(21):. PubMed ID: 29804567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint blockade - a treatment for urological cancers?
    Elhage O; Galustian C; Dasgupta P
    BJU Int; 2016 Oct; 118(4):498-500. PubMed ID: 27367558
    [No Abstract]   [Full Text] [Related]  

  • 29. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Checkpoint blockade after kidney transplantation.
    Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
    Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
    [No Abstract]   [Full Text] [Related]  

  • 31. Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors.
    Perez-Santos M
    Pharm Pat Anal; 2020 Sep; 9(5):149-154. PubMed ID: 32960139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint blockade therapy.
    Wieder T; Eigentler T; Brenner E; Röcken M
    J Allergy Clin Immunol; 2018 Nov; 142(5):1403-1414. PubMed ID: 29596939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
    Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
    Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
    [No Abstract]   [Full Text] [Related]  

  • 35. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
    Nadeau BA; Fecher LA; Owens SR; Razumilava N
    Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting immune checkpoints in non small cell lung cancer.
    Bianco A; Malapelle U; Rocco D; Perrotta F; Mazzarella G
    Curr Opin Pharmacol; 2018 Jun; 40():46-50. PubMed ID: 29525401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience.
    Kaur A; Doberstein T; Amberker RR; Garje R; Field EH; Singh N
    Medicine (Baltimore); 2019 Oct; 98(41):e17348. PubMed ID: 31593084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicities of checkpoint inhibitors: causes and management.
    Postow MA
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
    [No Abstract]   [Full Text] [Related]  

  • 39. Liver graft rejection following immune checkpoint inhibitors treatment: a review.
    Hu B; Yang XB; Sang XT
    Med Oncol; 2019 Oct; 36(11):94. PubMed ID: 31605245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.
    Samaan MA; Pavlidis P; Papa S; Powell N; Irving PM
    Nat Rev Gastroenterol Hepatol; 2018 Apr; 15(4):222-234. PubMed ID: 29512649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.